Klrg1 signaling therapy
AssigneeThe Brigham and Women's Hospital, Inc.
InventorsSteven Greenberg, Stefano Vincenzo Gulla, Kenneth Evan Thompson
Life of this patent
Estimating the term…
Abstract
A method of treating a subject can include administering to a subject in need thereof an effective amount of a killer cell lectin-like receptor G1 (KLRG1)/ligand binding agent, thereby disrupting KLRG1 signaling and activating CD8+ cytotoxic T and/or NK cells. A method of treating cancer can include administering to a subject in need thereof an effective amount of a killer cell lectin-like receptor G1 (KLRG1)/ligand binding agent. The methods can treat various cancers, for example melanoma, lung cancer, pancreatic cancer, glioma, breast cancer, and ovarian cancer.
Claims67
A method of treating a subject comprising administering to a subject in need thereof an effective amount of a killer cell lectin-like receptor G1 (KLRG1)/ligand binding agent, thereby disrupting KLRG1 signaling and activating CD8+ cytotoxic T and/or NK cells.
A method of treating cancer comprising administering to a subject in need thereof an effective amount of a killer cell lectin-like receptor G1 (KLRG1)/ligand binding agent.
A method of treating a melanoma comprising administering to a subject in need thereof an effective amount of a killer cell lectin-like receptor G1 (KLRG1)/ligand binding agent, wherein the binding agent is an antibody or antigen binding fragment thereof, or antibody mimetic that binds the extracellular domain of human KLRG1 and/or human E-cadherin, N-cadherin, or R-cadherin, thereby disrupting KLRG1 signaling and activating CD8+ cytotoxic T and/or NK cells.
A method of treating a lung cancer comprising administering to a subject in need thereof an effective amount of a killer cell lectin-like receptor G1 (KLRG1)/ligand binding agent, wherein the binding agent is an antibody or antigen binding fragment thereof, or antibody mimetic that binds the extracellular domain of human KLRG1 and/or human E-cadherin, N-cadherin, or R-cadherin, thereby disrupting KLRG1 signaling and activating CD8+ cytotoxic T and/or NK cells.
A method of treating a pancreatic cancer comprising administering to a subject in need thereof an effective amount of a killer cell lectin-like receptor G1 (KLRG1)/ligand binding agent, wherein the binding agent is an antibody or antigen binding fragment thereof, or antibody mimetic that binds the extracellular domain of human KLRG1 and/or human E-cadherin, N-cadherin, or R-cadherin, thereby disrupting KLRG1 signaling and activating CD8+ cytotoxic T and/or NK cells.
A method of treating a glioma comprising administering to a subject in need thereof an effective amount of a killer cell lectin-like receptor G1 (KLRG1)/ligand binding agent, wherein the binding agent is an antibody or antigen binding fragment thereof, or antibody mimetic that binds the extracellular domain of human KLRG1 and/or human E-cadherin, N-cadherin, or R-cadherin, thereby disrupting KLRG1 signaling and activating CD8+ cytotoxic T and/or NK cells.
A method of treating a breast cancer comprising administering to a subject in need thereof an effective amount of a killer cell lectin-like receptor G1 (KLRG1)/ligand binding agent, wherein the binding agent is an antibody or antigen binding fragment thereof, or antibody mimetic that binds the extracellular domain of human KLRG1 and/or human E-cadherin, N-cadherin, or R-cadherin, thereby disrupting KLRG1 signaling and activating CD8+ cytotoxic T and/or NK cells.
A method of treating an ovarian cancer comprising administering to a subject in need thereof an effective amount of a killer cell lectin-like receptor G1 (KLRG1)/ligand binding agent, wherein the binding agent is an antibody or antigen binding fragment thereof, or antibody mimetic that binds the extracellular domain of human KLRG1 and/or human E-cadherin, N-cadherin, or R-cadherin, thereby disrupting KLRG1 signaling and activating CD8+ cytotoxic T and/or NK cells.
A killer cell lectin-like receptor G1 (KLRG1) antagonist comprising (i) a killer cell lectin-like receptor G1 (KLRG1)/ligand binding agent or (ii) an RNAi agent that suppresses KLRG1 expression.
A method of treating a kidney cancer comprising administering to a subject in need thereof an effective amount of a killer cell lectin-like receptor G1 (KLRG1)/ligand binding agent, wherein the binding agent is an antibody or antigen binding fragment thereof, or antibody mimetic that binds the extracellular domain of human KLRG1 and/or human E-cadherin, N-cadherin, or R-cadherin, thereby disrupting KLRG1 signaling and activating CD8+ cytotoxic T and/or NK cells.
A killer cell lectin-like receptor G1 (KLRG1)/ligand binding agent that neutralizes KLRG1/cadherin binding and disrupts KLRG1 signaling, thereby activating CD8+ cytotoxic T and/or NK cells.
Dependencies are inferred from the claim text.